ArticleJournal of neural transmission (Vienna, Austria : 1996)2014
Automation of o-dianisidine assay for ceruloplasmin activity analyses: usefulness of investigation in Wilson's disease and in hepatic encephalopathy.
Article in Journal of neural transmission (Vienna, Austria : 1996), 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
15 citing papers in PubMed, 2 syntheses or guidelines pooled it, 40 citations in OpenAlex.
- Copper Imbalance in Alzheimer's Disease: Meta-Analysis of Serum, Plasma, and Brain Specimens, and Replication Study EvaluatingBiomolecules · 2021Pooled it
- Biomarkers for diagnosis of Wilson's disease.The Cochrane database of systematic reviews · 2019Pooled it
- Ceruloplasmin activity and iron chelation treatment of patients with Parkinson's disease.BMC neurology · 2015Trial
- Exchangeable Copper Excess and Zinc Deficiency in the Serum of Patients with Colorectal Cancer.Biological trace element research · 2025Article
- A new spectrophotometric method for measuring ceruloplasmin ferroxidase activity: an innovative approach.Biometals : an international journal on the role of metal ions in biology, biochemistry, and medicine · 2024Article
- Evaluation of Atherosclerotic Risk by Oxidative Contributors in Alcohol Use Disorder.Clinical psychopharmacology and neuroscience : the official scientific journal of the Korean College of Neuropsychopharmacology · 2023Article
- Development of a New Colorimetric, Kinetic and Automated Ceruloplasmin Ferroxidase Activity Measurement Method.Antioxidants (Basel, Switzerland) · 2022Article
- The Use of Biochemical Measurements to Identify Pre-Slaughter Stress in Pasture Finished Beef Cattle.Animals : an open access journal from MDPI · 2019Article
- Chloride Control of the Mechanism of Human Serum Ceruloplasmin (Cp) Catalysis.Journal of the American Chemical Society · 2019Article
- New tools for Wilson's disease diagnosis: exchangeable copper fraction.Annals of translational medicine · 2019Review
- Oxidative Stress Related to Iron Metabolism in Relapsing Remitting Multiple Sclerosis Patients With Low Disability.Frontiers in neuroscience · 2019Article
- Prognostic Value of Serum Copper for Post-Stroke Clinical Recovery: A Pilot Study.Frontiers in neurology · 2018Article
- An exploratory study of BDNF and oxidative stress marker alterations in subacute and chronic stroke patients affected by neuropathic pain.Journal of neural transmission (Vienna, Austria : 1996) · 2017Article
- Ceruloplasmin, a reliable marker of fibrosis in chronic hepatitis B virus patients with normal or minimally raised alanine aminotransferase.World journal of gastroenterology · 2016Article
- Altered metal metabolism in patients with HCV-related cirrhosis and hepatic encephalopathy.Metabolic brain disease · 2015Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 4 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Ceruloplasmin (Cp) is a serum ferroxidase that plays an essential role in iron metabolism. It is routinely tested by immunoturbidimetric assays that quantify the concentration of the protein both in its active and inactive forms. Cp activity is generally analyzed manually; the process is time-consuming, has a limited repeatability, and is not suitable for a clinical setting. To overcome these inconveniences, we have set the automation of the o-dianisidine Cp activity assay on a Cobas Mira Plus apparatus. The automation was rapid and repeatable, and the data were provided in terms of IU/L. The assay was adapted for human sera and showed a good precision [coefficient of variation (CV) 3.7 %] and low limit of detection (LoD 11.58 IU/L). The simultaneous analysis of Cp concentration and activity in the same run allowed us to calculate the Cp-specific activity that provides a better index of the overall Cp status. To test the usefulness of this automation, we tested this assay on 104 healthy volunteers and 36 patients with Wilson's disease, hepatic encephalopathy, and chronic liver disease. Cp activity and specific activity distinguished better patients between groups with respect to Cp concentration alone, and providing support for the clinical investigation of neurological diseases in which liver failure is one of the clinical hallmarks.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.